The Latest Cardiac and Vascular News
– First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. – BD’s COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million. – First fiscal quarter GAAP […]
– There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes – Compared with standard approaches, the BD vascular care solution reduced the relative risk of catheter failure by 27%, resulting in longer catheter dwell time […]
Polen to Succeed Vince Forlenza Effective April 28 FRANKLIN LAKES, N.J., Jan. 26, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of the BD board of directors, effective April 28, 2021. Polen will succeed Vincent A. Forlenza, who will […]
– Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis. – BD’s COVID-19 testing sales totaled more than $440 million in the fourth fiscal quarter. – Fiscal fourth quarter GAAP EPS were $0.36. Non-GAAP EPS were $2.79. FRANKLIN LAKES, N.J., Nov. 5, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) […]
Patrick Kaltenbach appointed chief technology officer Dave Hickey promoted to president, Life Sciences segment FRANKLIN LAKES, N.J., Oct. 22, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology officer, and the promotion of Dave Hickey to executive vice president and president, Life Sciences […]
– As reported, revenues of $4.225 billion increased 1.6 percent. – On a currency-neutral basis, revenues increased 2.5 percent. – As reported, diluted earnings per share of $0.87 decreased 57.6 percent. – As adjusted, diluted earnings per share of $2.65 decreased 1.9 percent, or 0.4 percent on a currency-neutral basis. – The company is lowering […]
FRANKLIN LAKES, N.J., Sept. 28, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug Coated Balloon (DCB) femoropopliteal clinical program in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. These data were simultaneously presented in a late-breaking session at […]
FRANKLIN LAKES, N.J., Sept. 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020, following the company’s annual meeting of shareholders. Forlenza will continue on the BD board of directors, serving as the executive chairman. The BD […]
– As reported, revenues of $4.350 billion increased 1.7 percent. – On a comparable, currency-neutral basis, revenues increased 5.7 percent. – As reported, diluted earnings per share of $1.51 decreased 25.6 percent. – As adjusted, diluted earnings per share of $3.08 increased 5.8 percent, or 14.8 percent on a currency-neutral basis. – The company reaffirms […]
FRANKLIN LAKES, N.J., June 20, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting related to the potential increase in mortality associated with the use of paclitaxel-coated devices […]
